Aniridia
17
4
4
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (17)
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
National Cohort on Congenital Defects of the Eye
Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures
RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy
Proteomic Study of Tears From Patients With a PAX6 Mutation
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Study of Ataluren in Participants With Nonsense Mutation Aniridia
Clinical Evaluation of Morcher Artificial Iris Diaphragms
Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Positive Angle Kappa
A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia
Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens